Scandinavian journal of rheumatology · 2026
Assessment of colchicine adherence and influencing factors in paediatric familial Mediterranean fever.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Erdem Torun Ş, Çelikel E, Ekici Tekin Z, Ertem Ş, Özçelik M A, Özçelik E, Polat M C, Öztürk D, Işıklar Ekici M, Uğur Es Y, Yoğun S N, Çelikel Acar B
Аннотация
OBJECTIVE: This study evaluated colchicine adherence in children and adolescents with familial Mediterranean fever (FMF) using the Medication Adherence Scale in FMF Patients (MASIF), and examined the influence of patient-related factors and family history.
METHOD: A cross-sectional study was conducted among 324 paediatric FMF patients (1-18 years old). Colchicine adherence was measured via MASIF, and demographic, clinical, genetic, and socioeconomic variables were analysed.
RESULTS: Of 324 patients (mean age 11.8 ± 3.8 years), 88 (27.2%) showed good adherence and 236 (72.8%) poor adherence. Adherence was not significantly associated with sex, age group, age at diagnosis, disease severity, family history, colchicine intolerance/resistance, or biologic use. Erysipelas-like erythema was present in 28 patients (8.6%) at diagnosis and correlated with better adherence (p = 0.016). Of the 142 patients (43.8%) who self-reported regular colchicine use, MASIF indicated poor adherence in 101 (71.1%). School absenteeism was reported in 41 (46.6%) of the adherent group and 171 (72.5%) of the non-adherent group (p < 0.001).
CONCLUSION: Colchicine non-adherence is frequent in paediatric FMF and largely unrelated to patient factors. Objective tools such as MASIF reveal higher non-adherence rates than self-reports and are essential for accurate evaluation in clinical decision making.
METHOD: A cross-sectional study was conducted among 324 paediatric FMF patients (1-18 years old). Colchicine adherence was measured via MASIF, and demographic, clinical, genetic, and socioeconomic variables were analysed.
RESULTS: Of 324 patients (mean age 11.8 ± 3.8 years), 88 (27.2%) showed good adherence and 236 (72.8%) poor adherence. Adherence was not significantly associated with sex, age group, age at diagnosis, disease severity, family history, colchicine intolerance/resistance, or biologic use. Erysipelas-like erythema was present in 28 patients (8.6%) at diagnosis and correlated with better adherence (p = 0.016). Of the 142 patients (43.8%) who self-reported regular colchicine use, MASIF indicated poor adherence in 101 (71.1%). School absenteeism was reported in 41 (46.6%) of the adherent group and 171 (72.5%) of the non-adherent group (p < 0.001).
CONCLUSION: Colchicine non-adherence is frequent in paediatric FMF and largely unrelated to patient factors. Objective tools such as MASIF reveal higher non-adherence rates than self-reports and are essential for accurate evaluation in clinical decision making.